JP2020513050A5 - - Google Patents

Download PDF

Info

Publication number
JP2020513050A5
JP2020513050A5 JP2019553932A JP2019553932A JP2020513050A5 JP 2020513050 A5 JP2020513050 A5 JP 2020513050A5 JP 2019553932 A JP2019553932 A JP 2019553932A JP 2019553932 A JP2019553932 A JP 2019553932A JP 2020513050 A5 JP2020513050 A5 JP 2020513050A5
Authority
JP
Japan
Prior art keywords
compound according
item
composition
alkyl
quencher
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019553932A
Other languages
English (en)
Japanese (ja)
Other versions
JP7149614B2 (ja
JP2020513050A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/025567 external-priority patent/WO2018183960A1/en
Publication of JP2020513050A publication Critical patent/JP2020513050A/ja
Publication of JP2020513050A5 publication Critical patent/JP2020513050A5/ja
Application granted granted Critical
Publication of JP7149614B2 publication Critical patent/JP7149614B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019553932A 2017-03-30 2018-03-30 ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤 Active JP7149614B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762478639P 2017-03-30 2017-03-30
US62/478,639 2017-03-30
PCT/US2018/025567 WO2018183960A1 (en) 2017-03-30 2018-03-30 Protease-activated contrast agents for in vivo imaging

Publications (3)

Publication Number Publication Date
JP2020513050A JP2020513050A (ja) 2020-04-30
JP2020513050A5 true JP2020513050A5 (enExample) 2021-05-06
JP7149614B2 JP7149614B2 (ja) 2022-10-07

Family

ID=63678348

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019553932A Active JP7149614B2 (ja) 2017-03-30 2018-03-30 ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤

Country Status (6)

Country Link
US (2) US11828752B2 (enExample)
EP (1) EP3601261A4 (enExample)
JP (1) JP7149614B2 (enExample)
KR (1) KR102669535B1 (enExample)
CN (1) CN110678460A (enExample)
WO (1) WO2018183960A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107406872B (zh) * 2015-01-22 2023-03-28 里兰斯坦福初级大学理事会 用于标记动物组织的化合物、组合物及其应用
WO2022203930A1 (en) * 2021-03-24 2022-09-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fluorogenic cyanine carbamates
CN116199662B (zh) * 2021-11-30 2024-10-11 中国科学院大连化学物理研究所 一种可见光和近红外光罗丹明荧光淬灭剂及其合成和应用
CN116199675B (zh) * 2021-11-30 2024-08-20 中国科学院大连化学物理研究所 一类罗丹明荧光淬灭剂及其合成和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60888A (en) 1978-06-16 1984-07-31 Yeda Res & Dev Substrates and process for the quantitative assay of enzymes
US5055451A (en) 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
AU2704395A (en) 1995-06-13 1997-01-09 Sanofi Winthrop, Inc. Calpain inhibitors for the treatment of neurodegenerative di seases
US6544951B2 (en) 1998-07-02 2003-04-08 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US20020052323A1 (en) 2000-08-30 2002-05-02 Jinhai Wang Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents
GB0112868D0 (en) 2001-05-25 2001-07-18 Secr Defence Detection system
US7303741B2 (en) 2002-09-23 2007-12-04 General Electric Company Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism
US20060148014A1 (en) 2004-12-09 2006-07-06 Sergei Agoulnik Tubulin isotype screening in cancer therapy using hemiasterlin analogs
US8968700B2 (en) 2005-08-11 2015-03-03 The Board Of Trustees Of The Leland Stanford Junior University Imaging of protease activity in live cells using activity based probes
MY162041A (en) * 2007-02-28 2017-05-31 Sanofi Aventis Imaging probes
CN101652149B (zh) 2007-02-28 2012-11-14 塞诺菲-安万特股份有限公司 成像探针
CA2695244A1 (en) 2007-08-03 2009-02-12 Sanofi-Aventis Caspase imaging probes
US20090214436A1 (en) 2008-02-18 2009-08-27 Washington University Dichromic fluorescent compounds
WO2009124265A1 (en) 2008-04-03 2009-10-08 The Board Of Trustees Of The Leland Stanford Junior University Probes for in vivo targeting of active cysteine proteases
US9155471B2 (en) 2009-05-27 2015-10-13 Lumicell, Inc'. Methods and systems for spatially identifying abnormal cells
WO2012021800A2 (en) 2010-08-13 2012-02-16 Banyan Biomarkers Caspase inhibitors as therapeutics for neural and organ injury and imaging
WO2012118715A2 (en) 2011-02-28 2012-09-07 The Board Of Trustees Of Leland Stanford Junior University Non-peptidic quenched fluorescent imaging probes
US8709830B2 (en) 2011-03-18 2014-04-29 Biotium, Inc. Fluorescent dyes, fluorescent dye kits, and methods of preparing labeled molecules
WO2013036743A1 (en) 2011-09-09 2013-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Imaging agents for imaging protease activity and uses thereof
US20140180073A1 (en) 2012-12-24 2014-06-26 Anticancer, Inc. Portable digital imaging system for fluorescence-guided surgery
KR20160037834A (ko) 2013-03-14 2016-04-06 루미셀, 아이엔씨. 의료 이미징 장치 및 사용 방법
WO2014145257A2 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use
WO2014171899A1 (en) 2013-04-19 2014-10-23 Agency For Science, Technology And Research Tunable fluorescence using cleavable linkers
US20170050988A1 (en) * 2013-11-25 2017-02-23 Sanofi Dotam derivatives for therapeutic use
CN107406872B (zh) * 2015-01-22 2023-03-28 里兰斯坦福初级大学理事会 用于标记动物组织的化合物、组合物及其应用

Similar Documents

Publication Publication Date Title
JP2020513050A5 (enExample)
ES2329542T3 (es) Bioconjugados de colorante de cianina e indocianina para aplicaciones biomedicas.
ES2385066T3 (es) Péptidos de unión a HGF marcados para la formación de imágenes
JP2016518341A5 (enExample)
US10278965B2 (en) Method of detecting cancer stem cell, method of screening cancer stem cell, and method of inhibiting cancer stem cell
CA2911414C (en) Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
US10220024B2 (en) Method of inhibiting cancer cell, method for detecting cancer cell, and system for detecting cancer cell
JP2018511556A5 (enExample)
CN105288645A (zh) 用于癌症靶向治疗的小分子配体-药物轭合物
JP2003500367A5 (enExample)
CN104203942A (zh) 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途
US10485773B2 (en) Benzenesulfonamide derivatives and method for treating cancer
US20100068148A1 (en) Enhanced resolution of tumor metastasis using a skin flap model
ES2923148T3 (es) Formulación y método de preparación
CN105431546A (zh) 基于活性的探针化合物、组合物及其使用方法
JP2019511497A5 (enExample)
ES2331562T3 (es) Profarmacos de agentes anticancerigenos que emplean acidos aromaticos sustituidos.
CN113717543B (zh) 一种七甲川菁近红外染料及其应用
CA3136294A1 (en) Ir700 nanocompositions for cardiac therapies and applications
ES2343674T3 (es) Farmacos preventivos o curativos para el endometriosis.
AU2002326872A1 (en) Enhanced resolution of tumor metastasis
ES2745506T3 (es) Combinación antitumoral que comprende cabazitaxel y cisplatino
Wada et al. Leiomyosarcoma in the maxilla: A case report
RU2219928C2 (ru) Средства для лечения и профилактики неоплазм
ES2309222T3 (es) Inhibidores no nucleosidos de la transcriptasa inversa como antagonistas de la proliferacion celular e inductores de la diferenciacion celular.